Fig 1.
The role of CKMT1B level as prognostic factor for survival and the association with grade.
(A) The expression of CKMT1B between normal and tumor tissues from GEPIA database. (B) Survival curve of differential CKMT1B expression were analyzed by GEPIA. (C) Differential expression of CKMT1B in different grade from TCGA database. (D) Survival curve of differential CKMT1B expression were analyzed in validation set from CGGA database. Abbreviations: CKMT1B, Creatine Kinase, Mitochondrial 1B; LGG, Lower-grade glioma; GEPIA, Gene Expression Profiling Interactive Analysis; CGGA, Chinese Glioma Genome Atlas.
Fig 2.
Multivariate Cox analysis of the correlation of CKMT1B expression with overall survival from TCGA database.
Table 1.
Variables related to overall survival: Cox regression analysis.
Fig 3.
(A) KEGG showed five signaling pathways in CKMT1B high and low expression groups by GSEA. (B) GSEA analysis revealed differential enrichment of genes in GO with CKMT1B high and low expression groups. (NES ≥2.0, NOM p-value < 0.05, FDR q-value <0.05). Abbreviations: GSEA, Gene Set Enrichment Analysis; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Table 2.
Gene sets enriched in phenotype.
Fig 4.
The varied proportions of 22 subtypes of immune cells in high and low CKMT1B groups in tumor samples.
Horizontal and vertical axes respectively represent TIICs and relative percentages. Blue and red colors represent low and high CKMT1B expression groups, respectively.
Fig 5.
(A) CKMT1B expression level has significant negative correlations with infiltrating levels of B cell, CD8+ T cells, CD4+ T cells, dendritic cells, Macrophages and Neutrophils. (B) The B cells, CD4+ T cells, CD8+ T cells, dendritic cells, Macrophages and Neutrophils are correlated with the cumulative survival rate in LGG.